IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
1
Neutral
7
Bullish
6
Bearish
7
Neutral
7
Bullish
32
Bearish
6
Neutral
0
Bullish
26
Aspira Pathlab & Diagnostics Limited operates diagnostic centres and pathology laboratories, providing pathology and radiology investigations, servicing individual patients, hospitals and healthcare providers primarily across Maharashtra while claiming wider pan-India reach; the company follows an asset-light model with technology-led patient engagement and a focus on regional consolidation before scaling operations nationally.
Financially, the company reported healthy quarter results for Q2 ended September 30, 2025 with revenue from operations of ₹809.28 lakh and PAT of ₹183.54 lakh, delivering a six‑month revenue of approximately ₹1,334.08 lakh and PAT of ₹230.49 lakh, driven by higher volumes, controlled operating expenses and an unmodified limited review report from the statutory auditor.
Cash flow dynamics show a material divergence between accounting profit and operating cash generation: operating profit before working capital was ₹289.19 lakh for the period but net cash from operations was only ₹15.69 lakh, driven by a sharp build-up in trade receivables to ₹371.35 lakh and elevated working capital requirements that are tightening near-term liquidity.
Balance sheet and capital structure exhibit moderate leverage with non-current borrowings of ₹127.88 lakh, significant right-of-use assets and lease liabilities reflecting an asset-light but leased-network model, total equity rising to ₹1,442.34 lakh and total assets growing to ₹2,016.30 lakh, indicating modest funded growth and retained earnings accumulation through the half year.
Corporate actions include a small slump-sale acquisition of Aspira DNA Diagnostics Gujarat LLP for ₹13.00 lakh effective July 1, 2025 with subsequent winding up of the LLP, and governance strengthening via appointment of an experienced independent director; the acquisition is immaterial to scale but removes the associate LLP and simplifies reporting to standalone results.
Healthcare Services
Healthcare Service Provider
133 Cr
Low Risk
55.4
59.7
0.3
18.4
149.99
49.00
Sales CAGR
Profit CAGR
ROE
ROCE
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Aspira Pathlab & Diagnostics Ltd (ASPIRA) is currently trading at 129.15 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Aspira Pathlab & Diagnostics Limited operates diagnostic centres and pathology laboratories, providing pathology and radiology investigations, servicing individual patients, hospitals and healthcare providers primarily across Maharashtra while claiming wider pan-India reach; the company follows an asset-light model with technology-led patient engagement and a focus on regional consolidation before scaling operations nationally. Financially, the company reported healthy quarter results for Q2 ended September 30, 2025 with revenue from operations of ₹809.28 lakh and PAT of ₹183.54 lakh, delivering a six‑month revenue of approximately ₹1,334.08 lakh and PAT of ₹230.49 lakh, driven by higher volumes, controlled operating expenses and an unmodified limited review report from the statutory auditor. Cash flow dynamics show a material divergence between accounting profit and operating cash generation: operating profit before working capital was ₹289.19 lakh for the period but net cash from operations was only ₹15.69 lakh, driven by a sharp build-up in trade receivables to ₹371.35 lakh and elevated working capital requirements that are tightening near-term liquidity. Balance sheet and capital structure exhibit moderate leverage with non-current borrowings of ₹127.88 lakh, significant right-of-use assets and lease liabilities reflecting an asset-light but leased-network model, total equity rising to ₹1,442.34 lakh and total assets growing to ₹2,016.30 lakh, indicating modest funded growth and retained earnings accumulation through the half year. Corporate actions include a small slump-sale acquisition of Aspira DNA Diagnostics Gujarat LLP for ₹13.00 lakh effective July 1, 2025 with subsequent winding up of the LLP, and governance strengthening via appointment of an experienced independent director; the acquisition is immaterial to scale but removes the associate LLP and simplifies reporting to standalone results.
Over the past 52 weeks, Aspira Pathlab & Diagnostics Ltd has traded between a low of ₹49.00 and a high of ₹149.99. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Aspira Pathlab & Diagnostics Ltd has a market capitalization of approximately 132.93. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Aspira Pathlab & Diagnostics Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 55.39 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 132.93 Cr, Aspira Pathlab & Diagnostics Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Aspira Pathlab & Diagnostics Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Aspira Pathlab & Diagnostics Ltd is 55.39. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
93.25 | 154 Cr | 19.31 | 2.70 | 0.00 | 5.93 | 8.44 | 0.00 | ||
141.00 | 148 Cr | 37.62 | 2.07 | 0.00 | 4.56 | 5.17 | 3.07 | ||
198.60 | 138 Cr | 64.04 | 5.41 | 0.00 | 5.87 | 8.80 | 3.00 | ||
69.00 | 135 Cr | 26.85 | 2.57 | 0.00 | 9.53 | 9.10 | 0.00 | ||
129.15 | 133 Cr | 55.39 | 18.37 | 0.00 | 16.62 | 13.17 | 13.75 | ||
67.35 | 117 Cr | 6.88 | 1.01 | 0.00 | 16.61 | 20.64 | 11.10 | ||
83.00 | 104 Cr | 21.25 | 2.09 | 0.00 | 9.83 | 13.44 | 8.08 | ||
| Median: 7 Co. | — | 93.25 | 135 Cr | 26.85 | 2.57 | 0.00 | 9.53 | 9.10 | 3.07 |
